Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Ocelot Bio logo — Developing innovative therapeutics to significantly improve...

Ocelot Bio

Developing innovative therapeutics to significantly improve outcomes for patients with end-stage liver disease

Founded 2020 United States Redwood City, United States 4 employees Debt Financing Biotechnology, Health Care +1

General Information

Company Name Ocelot Bio
Founded Year 2020
Location United States Redwood City, United States
Employees 4
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with Ocelot Bio. To contact Ocelot Bio, visit ocelotbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ocelot Bio compare?

A PDF of Ocelot Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ocelot Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ocelot Bio

Ocelot Bio is a clinical-stage biopharmaceutical company that is dedicated to developing innovative therapeutics aimed at improving outcomes for patients with liver disease, particularly end-stage liver disease (ESLD). The company's lead clinical candidate, OCE-205, is a therapeutic peptide designed to selectively address complications induced by portal hypertension in patients with ESLD, such as hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites, which could potentially lead to serious and life-threatening outcomes. Ocelot Bio has begun a Phase 2 clinical trial of OCE-205 in HRS-AKI, and the U.S. Food & Drug Administration (FDA) has granted OCE-205 Orphan Drug Designation in the treatment of hepatorenal syndrome. Founded in 2020 by leading experts in therapeutic peptide development, Ocelot Bio has garnered support from a strong syndicate of investors, including Venrock, RA Capital Management, and Vivo Capital. The company's core focus lies in the biotechnology, health care, and life sciences industries, with its headquarters based in the United States. For further details, one can access additional information on the company by visiting www.ocelotbio.com.

No funding data available for Ocelot Bio yet.

Ocelot Bio Alternatives & Competitors

Ocelot Bio vs
Vital Therapies
Vital Therapies

Pioneering the future of liver therapy with innovative cell-based treatments for acute liver failure...

Private Equity
Biotechnology, Health Care

FAQ About Ocelot Bio

Developing innovative therapeutics to significantly improve outcomes for patients with end-stage liver disease
Ocelot Bio was founded in 2020.
Ocelot Bio is headquartered in Redwood City, United States.
Ocelot Bio operates in Biotechnology, Health Care and Life Sciences.
Ocelot Bio has approximately 4 employees.
Top alternatives and competitors to Ocelot Bio include Vital Therapies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ocelot Bio and Vital Therapies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ocelot Bio, https://bouncewatch.com/company/ocelot-bio, updated 7 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes